[go: up one dir, main page]

PE20081545A1 - Derivados de sulfonamida como inhibidores de acido graso sintasas - Google Patents

Derivados de sulfonamida como inhibidores de acido graso sintasas

Info

Publication number
PE20081545A1
PE20081545A1 PE2008000005A PE2008000005A PE20081545A1 PE 20081545 A1 PE20081545 A1 PE 20081545A1 PE 2008000005 A PE2008000005 A PE 2008000005A PE 2008000005 A PE2008000005 A PE 2008000005A PE 20081545 A1 PE20081545 A1 PE 20081545A1
Authority
PE
Peru
Prior art keywords
halo
alkyl
fatty acid
cyane
alcoxy
Prior art date
Application number
PE2008000005A
Other languages
English (en)
Inventor
Roger John Butlin
Peter William Rodney Caulkett
Andrew Leach
Nicholas John Newcombe
Charles John O'donnell
Helen Pointon
James Mathew Wood
Petra Johannesson
Laurent Daniel Knerr
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20081545A1 publication Critical patent/PE20081545A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

REFERIDA A UN DERIVADO DE SULFONAMIDA DE FORMULA (I), DONDE R1 ES ALQUILO C1-C6, CICLOALQUILO C3-C10, ALQUINILO C2-C6, ENTRE OTROS; R2 ES H, CIANO, HALO,ALCOXI C1-C3, ENTRE OTROS; R3 ES H, CIANO, HALO, ALCOXI C1-C3, ENTRE OTROS; R4 ES ALQUILO C1-C3, ALCOXI C1-C3, HALO, ENTRE OTROS; R5 Y R5' SON H, HALO, CIANO, ALQUILO C1-C3, ENTRE OTROS; R6 Y R6' SON H, HALO, CIANO, ALQUILO C1-C3, ENTRE OTROS; R7 ES H U OH. SON COMPUESTOS PREFERIDOS: N-[5-[4-(4-CIANOFENIL)PIPERIDIN-1-CARBONIL]-2-METIL-FENIL]METANSULFONAMIDA, N-[5-[4-(4-CIANOFENIL)PIPERIDIN-1-CARBONIL]-2-METIL-FENIL]-2-FLUORO-BENCENSULFONAMIDA, 4-CLORO-N-[5-[4-(4-CIANOFENIL)PIPERIDIN-1-CARBONIL-2-METIL-FENIL]BENCENSULFONAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN METODO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACIDO GRASO SINTASA (FAS) Y SON UTILES EN EL TRATAMIENTO DE LA OBESIDAD Y DIABETES MELLITUS
PE2008000005A 2006-12-21 2008-01-02 Derivados de sulfonamida como inhibidores de acido graso sintasas PE20081545A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87119206P 2006-12-21 2006-12-21
US91023207P 2007-04-05 2007-04-05

Publications (1)

Publication Number Publication Date
PE20081545A1 true PE20081545A1 (es) 2009-01-11

Family

ID=39166817

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000005A PE20081545A1 (es) 2006-12-21 2008-01-02 Derivados de sulfonamida como inhibidores de acido graso sintasas

Country Status (7)

Country Link
US (1) US20090105305A1 (es)
AR (1) AR064495A1 (es)
CL (1) CL2007003803A1 (es)
PE (1) PE20081545A1 (es)
TW (1) TW200831092A (es)
UY (1) UY30809A1 (es)
WO (1) WO2008075070A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
US8841334B2 (en) * 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
EP2024349B1 (en) * 2006-05-31 2017-08-02 AbbVie Inc. Compounds as cannabinoid receptor ligands and uses thereof
MX2009010363A (es) 2007-03-28 2009-12-04 Abbott Lab Compuestos de 1,3-tiazol-2(3h)-ilideno como ligandos del receptor canabinoide.
US7872033B2 (en) * 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
CN101711253A (zh) * 2007-05-18 2010-05-19 雅培制药有限公司 用作大麻素受体配体的新化合物
US9193713B2 (en) * 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
JP2011513495A (ja) * 2008-03-11 2011-04-28 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしての新規な化合物
US8404866B2 (en) 2008-09-03 2013-03-26 Florida State University Research Foundation Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors
US8846730B2 (en) * 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2010033543A2 (en) * 2008-09-16 2010-03-25 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
PA8854001A1 (es) * 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
AR075442A1 (es) * 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US20130237535A1 (en) * 2010-11-08 2013-09-12 Nicholas D. Adams Fatty acid synthase inhibitors
US20170119786A1 (en) 2011-03-08 2017-05-04 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
US9624173B2 (en) 2011-03-08 2017-04-18 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
LT2683244T (lt) * 2011-03-08 2017-04-10 3-V Biosciences, Inc. Lipidų sintezės heterocikliniai moduliatoriai
TWI522348B (zh) 2011-03-08 2016-02-21 ３ Ｖ生物科技公司 脂質合成之雜環調節劑
US9084794B2 (en) 2011-08-19 2015-07-21 Glaxosmithkline Intellectual Property (No. 2) Limited Fatty acid synthase inhibitors
CN104080777B (zh) * 2012-01-31 2015-12-09 伊莱利利公司 用作mogat-2抑制剂的吗啉基衍生物
IN2015DN00137A (es) * 2012-07-03 2015-06-12 3 V Biosciences Inc
JP2016501844A (ja) * 2012-11-06 2016-01-21 イーライ リリー アンド カンパニー ＭｏＧＡＴ−２阻害剤として有用な新規のベンジルスルホンアミド化合物
CN103420824B (zh) * 2012-11-19 2015-06-17 烟台万润精细化工股份有限公司 烷氧基甲基苯甲酸的制备方法
MX364895B (es) 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.
EP3077387B1 (en) * 2013-12-03 2017-12-20 Janssen Pharmaceutica NV Benzamide derivative useful as fasn inhibitors for the treatment of cancer
ES2841137T3 (es) 2013-12-20 2021-07-07 Sagimet Biosciences Inc Moduladores heterocíclicos de la síntesis de lípidos y combinaciones de los mismos
RU2766087C2 (ru) * 2014-01-07 2022-02-07 Сагимет Байосайенсиз Инк. Гетероциклические модуляторы синтеза липидов для применения против рака и вирусных инфекций
JP6691909B2 (ja) 2014-08-15 2020-05-13 サギメット バイオサイエンシーズ インコーポレイテッド 薬物耐性癌の治療で用いるための脂肪酸シンターゼ阻害剤
CN107428728A (zh) 2015-03-19 2017-12-01 3-V生物科学股份有限公司 脂质合成的杂环调节剂
CN107847765B (zh) 2015-06-18 2021-05-04 89生物有限公司 1,4-取代的哌啶衍生物
CA3014432C (en) 2015-06-18 2024-05-07 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
CN105130921B (zh) * 2015-07-29 2018-04-06 广州市广金投资管理有限公司 芳基哌嗪衍生物ⅰ及其盐、制备方法和用途
CN105153145B (zh) * 2015-07-29 2018-10-30 广州市广金投资管理有限公司 芳基哌嗪衍生物ⅱ及其盐、制备方法和用途
EP3538088A1 (en) * 2016-11-11 2019-09-18 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
TW202012396A (zh) * 2018-04-18 2020-04-01 美商德洛斯股份有限公司 具乙烯磺醯胺部分之k-ras調節劑
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
US20240261296A1 (en) 2021-04-07 2024-08-08 Hadasit Medical Research Serices & Development Ltd. Therapeutic modalities for inhibiting pancreatic beta cell impairment and treating diabetes
WO2022217239A1 (en) * 2021-04-09 2022-10-13 Board Of Regents, The University Of Texas System Inhibitors of pu.1 for the treatment of disease
WO2025120168A1 (en) 2023-12-07 2025-06-12 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement (Inrae) Sulfonamide derivatives and use thereof in the treatment of cryptosporidium infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423704B2 (en) * 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
MXPA05006354A (es) * 2002-12-13 2005-08-26 Smithkline Beecham Corp Antagonistas ccr5 como agentes terapeuticos.
WO2007052843A1 (ja) * 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途

Also Published As

Publication number Publication date
US20090105305A1 (en) 2009-04-23
CL2007003803A1 (es) 2008-08-01
UY30809A1 (es) 2008-07-31
TW200831092A (en) 2008-08-01
WO2008075070A1 (en) 2008-06-26
AR064495A1 (es) 2009-04-08

Similar Documents

Publication Publication Date Title
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
PE20081836A1 (es) Derivados de piperidina como inhibidores de la sintasa de acido graso
PE20090813A1 (es) Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa
PE20080843A1 (es) Inhibidores de renina y metodo para su utilizacion
PE20050948A1 (es) Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
PE20021014A1 (es) Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad
PE20120355A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20110136A1 (es) Compuestos organicos
PE20061357A1 (es) COMPUESTOS DERIVADOS DE AMINOSULFONILO COMO INHIBIDORES DE LA 11-ß-HSD-1
PE20131463A1 (es) Piperidino-dihidrotienopirimidinas sustituidas
PE20070833A1 (es) Compuestos de pirimidinil benzotiofeno
UY31986A (es) Derivados n- sustituídos de la 2-metil-propionamida;{1-[5-sustiuido-4-sustituido-tiazol-2-il-carbamoil]-1-metil-etil} amidas de ácidos carboxílicos sustituidos, derivados farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20130384A1 (es) Derivados de benzotiazepina
PE20081487A1 (es) DERIVADOS DE NICOTINAMIDA COMO INHIBIDORES DE 11ßHSD1
PE20020476A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20081532A1 (es) Compuestos novedosos
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20110796A1 (es) (s)-1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il}-amida) de 2-amida del acido pirrolidin-1,2-dicarboxilico como inhibidor de la cinasa de fosfatidilinositol (pi3k)
EA200901662A1 (ru) Агонисты фарнезоидного х-рецептора
PE20071223A1 (es) Procedimiento de preparacion de derivados de acil-amino-alquilen-amida
PE20080538A1 (es) Derivado heterociclico fusionado y su uso
PE20121640A1 (es) Derivados de pirazina como inhibidores de bace
PE20080768A1 (es) Compuestos de isoindolina 5-sustituidos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal